T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts

PHASE2CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

April 30, 2000

Primary Completion Date

November 30, 2015

Study Completion Date

November 30, 2016

Conditions
Acute Lymphoblastic LeukemiaNon Hodgkins LymphomaMyelodysplastic SyndromeAcute Myeloid LeukemiaChronic Myelogenous LeukemiaHemophagocytic Lymphohistiocytosis (HLH)Familial Hemophagocytic Lymphohistiocytosis (FLH)Viral-associated Hemophagocytic Syndrome (VAHS)X-linked Lymphoproliferative Disease (XLP)
Interventions
DRUG

Ara-C

"day-8 through day-5~3 g/m2 q 12 hours"

DRUG

Cyclophosphamide

"day-7 and day-6~45 mg/kg"

BIOLOGICAL

Campath-1H

"day-3 through day-1~Dosing for children:~5 - 15kg : 3mg IV in 30ml NS~15.1 - 30kg : 5mg IV in 50ml NS~\>30 kg : 10mg IV in 100ml NS~Adults will receive 10mg IV in 100ml NS"

RADIATION

Total Body Irradiation

"day-4 through day-1~175 cGy x 2 at 24 cGy/min"

PROCEDURE

Stem Cell Infusion

Stem cells are infused on day 0

Trial Locations (2)

77030

Houston Methodist Hospital, Houston

Texas Children's Hosptial, Houston

All Listed Sponsors
collaborator

Center for Cell and Gene Therapy, Baylor College of Medicine

OTHER

collaborator

The Methodist Hospital Research Institute

OTHER

lead

Baylor College of Medicine

OTHER

NCT00368355 - T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts | Biotech Hunter | Biotech Hunter